{"entity":{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of STI-6129 in multiple myeloma, run by Zhejiang ACEA Pharmaceutical Co. Ltd., now recruiting.","summary":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05565807 by Zhejiang ACEA Pharmaceutical Co. Ltd., with 84 participants planned, started 2023-02-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: STI-6129. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05565807","url":"https://clinicaltrials.gov/study/NCT05565807"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["sti-6129"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05565807","phase":"1/2","setting":"A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","enrolled":84,"outcomes":[]},"route":"/trials/nct05565807/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"sti-6129","kind":"drug","name":"STI-6129","route":"/drugs/sti-6129/"}]}}